Adjuvant and neoadjuvant radiotherapy in bladder cancer treatment end results were not satisfactory during the last 3–4 decades, mainly owing to improper selection of patients and owing to the ...

PTV-15 mm: CTV bladder plus 15 mm uniform margin ... 48% of patients received neoadjuvant or adjuvant radiotherapy and/or chemotherapy. § 24% of patients received postoperative radiotherapy.

In the AS group, 17 patients (68%) had some recurrence and 12 (48%) were metastasis-free with an intact bladder. The 2-year overall survival (OS) was 84.3% (95% CI, 73.4 to 91.0); OS was 88.0% (95% CI ...

Biomarker-driven treatment for muscle-invasive bladder cancer (MIBC) led to a 2-year metastasis-free survival (MFS) rate that ...

In January 2024, the FDA approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial ...

Robot-assisted partial cystectomy following neoadjuvant chemotherapy in selected patients may be a bladder-preserving option for patients with muscle-invasive bladder cancer. Robot-assisted ...

The following is a summary of “Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive ...

AstraZeneca AZN announced that the FDA has accepted and granted priority review to its supplemental biologics license ...

FDA grants Priority Review to AstraZeneca’s Imfinzi sBLA for muscle-invasive bladder ... Lung Cancer In the trial, patients were treated with Imfinzi in combination with neoadjuvant chemotherapy ...

The sBLA seeks approval of Imfinzi for the treatment of patients with muscle-invasive bladder cancer (MIBC ... when used in combination with neoadjuvant chemotherapy before radical cystectomy ...

"Our data support camrelizumab plus chemotherapy as a potential new neoadjuvant therapeutic option for treating early or locally advanced triple-negative breast cancer," said Shao. NSABP B-59/GBG ...